Michael Teneriello

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Carol Aghajanian, Stephanie V. Blank, Barbara A. Goff et al. · Journal of Clinical Oncology · 2012 · 1.4K citations · Full text

Medicine, Gynecology, Oncology +16

Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer

David G. Mutch, Mauro Orlando, T. Goss et al. · Journal of Clinical Oncology · 2007 · 441 citations · Full text

Medicine, Oncology, Pharmacology +15

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

R. Wendel Naumann, Robert L. Coleman, Robert A. Burger et al. · Journal of Clinical Oncology · 2013 · 233 citations

Medicine, Oncology, Pharmacology +16

p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.

Michael Teneriello, Masahito Ebina, R. Ilona Linnoila et al. · PubMed · 1993 · 213 citations

Medicine, Genetics, Oncology +17

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse

Ignace Vergote, Deborah K. Armstrong, Giovanni Scambia et al. · Journal of Clinical Oncology · 2016 · 159 citations · Full text

Medicine, Oncology, Pharmacology +17